Physician profile
Sheldon L Stern
NPI 1255300075
$5,870.84
in general payments reported to CMS, 2019-2025
30 companies · $885 in 2025
The $885 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,751 · 2020: $361 · 2021: $301 · 2022: $655 · 2023: $918 · 2024: $1,001 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.31 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,089.45 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $808.88 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $487.11 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $397.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $339.49 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $332.20 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $321.79 | 2019-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $244.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.40 | 2019-2025 | Ofev, Jardiance |
| Merck Sharp & Dohme LLC | $211.33 | 2019-2024 | Gardasil 9, Gardasil, Vaxelis |
| Abbvie INC. | $195.62 | 2022-2024 | Linzess, Viberzi |
| Alk-Abello, INC | $161.31 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Exact Sciences Corporation | $137.34 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.88 | 2019-2020 | |
| Medtronic, INC. | $87.15 | 2023 | Minimed 770g, Inpen Smart Insulin Delivery System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $84.72 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $84.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.28 | 2022 | |
| Amneal Pharmaceuticals LLC | $66.82 | 2023-2025 | Unithroid |
| Ironshore Pharmaceuticals INC. | $59.33 | 2019 | |
| Amarin Pharma, INC. | $54.50 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $53.08 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $47.16 | 2019-2020 | |
| Eisai INC. | $26.77 | 2019 | |
| Esperion Therapeutics, INC. | $24.22 | 2021 | |
| Allergan, INC. | $22.81 | 2020 | |
| Boston Scientific Corporation | $22.18 | 2025 | General - Pain Management |
| Shire North American Group INC | $16.43 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.31 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.